Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 6; p. 877
• Main Authors: You, Shen, Wang, Ming-Jin, Hou, Zhen-Yan, Wang, Wei-Da, Du, Ting-Ting, Xue, Ni-Na, Ji, Ming, Chen, Xiao-Guang
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2023; MDPI
• Subjects: acetyl-CoA acetyltransferase; Analysis; Cancer therapies; Care and treatment; Cell cycle; Cell differentiation; Chemotherapy; chlorogenic acid; Cytotoxicity; differentiation; Discriminant analysis; Enzymes; Health aspects; Identification and classification; Immunotherapy; Ions; Metabolism; Metabolites; Neuroblastoma; Phenols; thiamine; Tumors; Vitamin B; China; neuroblastoma; thiamine; differentiation; acetyl-CoA acetyltransferase; chlorogenic acid
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16060877

Background: Chlorogenic acid (CHA) has been shown to have substantial biological activities, including anti-inflammatory, antioxidant, and antitumor effects. However, the pharmacological role of CHA in neuroblastoma has not yet been assessed. Neuroblastoma is a type of cancer that develops in undifferentiated sympathetic ganglion cells. This study aims to assess the antitumor activity of CHA against neuroblastoma and reveal its mechanism of action in cell differentiation. Methods: Be(2)-M17 and SH-SY5Y neuroblastoma cells were used to confirm the differentiation phenotype. Subcutaneous and orthotopic xenograft mouse models were also used to evaluate the antitumor activity of CHA. Seahorse assays and metabolomic analyses were further performed to investigate the roles of CHA and its target ACAT1 in mitochondrial metabolism. Results: CHA induced the differentiation of Be(2)-M17 and SH-SY5Y neuroblastoma cells in vivo and in vitro. The knockdown of mitochondrial ACAT1, which was inhibited by CHA, also resulted in differentiation characteristics in vivo and in vitro. A metabolomic analysis revealed that thiamine metabolism was involved in the differentiation of neuroblastoma cells. Conclusions: These results provide evidence that CHA shows good antitumor activity against neuroblastoma via the induction of differentiation, by which the ACAT1-TPK1-PDH pathway is involved. CHA is a potential drug candidate for neuroblastoma therapy.